RxDoctor Payments Data

Scott Rypkema, MD

Cardiovascular Disease · Little Rock, ARNPI 1376586214

Payments from drug & device makers

$3,880in general payments, 2019–2025

Across 288 payments — averaging $13.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Pfizer$504
  • Amgen$470
  • E.r. Squibb & Sons, L.L.C.$229
  • Johnson & Johnson$224
  • AstraZeneca$128
  • plus $485 from 13 others

What the payments were for

  • Food & beverage$3,880100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,880 in reported general payments places this provider in the 50th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$204,770
Medicare patients
1,094
Services billed
3,000

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban566$454,528
XareltoRivaroxaban138$118,383
EntrestoSacubitril/Valsartan94$90,567
FarxigaDapagliflozin Propanediol46$39,498
MultaqDronedarone Hcl22$28,552
JardianceEmpagliflozin31$27,653
Repatha SureclickEvolocumab29$26,454
Metoprolol Succinate533$7,570
Atorvastatin Calcium713$6,686
Nebivolol Hcl43$3,976
Irbesartan139$3,587
Potassium Chloride193$2,728
Losartan Potassium274$2,653
Amlodipine Besylate341$2,259
Ranolazine ErRanolazine48$2,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$504$454,528566 claims
Johnson & JohnsonXarelto$224$118,383138 claims
NovartisEntresto$1,841$90,56794 claims
AstraZenecaFarxiga$128$39,49846 claims
Sanofi-aventis U.S. LLCMultaq$15$28,55222 claims
Boehringer IngelheimJardiance$80$27,65331 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →